The application of qNMR for the determination of rosuvastatin in tablet form

In this study, quantative nuclear magnetic resonance (qNMR) method was used to determine the content of rosuvastatin in tablet. Linearity, range, limit of detection (LOD), limit of quantification (LOQ), accuracy, and precision were determined in validation study of rosuvastatin. Furthermore, validation study of rosuvastatin was performed with high performance liquid chromatography (HPLC). Uncertainties of qNMR and HPLC methods were determined using per EURACHEM/CITAC Guide CG 4 (3th edition), quantifying uncertainty in analytical measurement. qNMR and HPLC methods were linear in the ranges of 0.10 - 5.00 mg/mL and 0.001 - 0.0995 mg/mL, respectively and these lineraties indicate very good linearity performance with regression coefficients (R2 value) above > 0.99. Moreover, LOD and LOQ values using qNMR method were observed as 0.25 mg/mL and 0.80 mg/mL, respectively. These values using HPLC method were found as 0.00051 mu g/mL and 0.001695 mu g/mL, respectively. The strengths and weaknesses of qNMR method and HPLC method were determined with spectral emphasis on the role of identical reference standards in qualitive and quantitative analyses. It was found that qNMR method is simple, efficient, reliable, and accurate method. Moreover, qNMR method is an easy, practical, and useful method for the validation and optimization of rosuvastatin in the tablet.

Keywords:

qNMR, proton nuclear magnetic resonance, high performance liquid chromatography rosuvastatin, validation,

PDF

___

Adams LS, 2010, CANCER PREV RES, V3, P108, DOI 10.1158/1940-6207.CAPR-08-0225
Ashour Safwan, 2011, Int J Biomed Sci, V7, P283
Chen XL, 2016, J PHARMACEUT BIOMED, V124, P281, DOI 10.1016/j.jpba.2016.02.016
EURACHEM, 2012, CITAC GUIDE CG 4 .
Goger NG, 2000, J PHARM BIOMED ANAL, V21, P685, DOI [10.1016/s0731-7085(99)00156-9, DOI 10.1016/S0731-7085(99)00156-9]
Gomes FP, 2009, ANAL LETT, V42, P1784, DOI 10.1080/00032710903060669
GUM, 2014, GUID EXPR UNC MEAS .
Holzgrabe U, 2005, J PHARMACEUT BIOMED, V38, P806, DOI 10.1016/j.jpba.2005.01.050
Holzgrabe U, 2010, PROG NUCL MAG RES SP, V57, P229, DOI 10.1016/j.pnmrs.2010.05.001
ICH Q2(R1), 2005, HARM TRIP GUID VAL A .
Kaila HO, 2010, INDIAN J PHARM SCI, V72, P592, DOI 10.4103/0250-474X.78526
Kumar TR, 2006, BIOMED CHROMATOGR, V20, P881, DOI 10.1002/bmc.611
Liang XR, 2014, MAGN RESON CHEM, V52, P178, DOI 10.1002/mrc.4048
Malz F, 2005, J PHARMACEUT BIOMED, V38, P813, DOI 10.1016/j.jpba.2005.01.043
Ohtsuki T, 2012, TALANTA, V99, P342, DOI 10.1016/j.talanta.2012.05.062
Pauli GF, 2005, J NAT PROD, V68, P133, DOI 10.1021/np0497301
Pauli GF, 2001, PHYTOCHEM ANALYSIS, V12, P28, DOI 10.1002/1099-1565(200101/02)12:1<28::AID-PCA549>3.0.CO;2-D
Pauli GF, 2007, J NAT PROD, V70, P589, DOI 10.1021/np060535r
Schoenberger T, 2012, ANAL BIOANAL CHEM, V403, P247, DOI 10.1007/s00216-012-5777-1
Simmler C, 2014, CURR OPIN BIOTECH, V25, P51, DOI 10.1016/j.copbio.2013.08.004
Sun SS, 2017, MOLECULES, V22, DOI 10.3390/molecules22091517
Un I, 2016, J CHEM METROL, V10, P1 .
Wang N, 2012, BREAST CANCER RES TR, V134, P943, DOI 10.1007/s10549-012-1977-9
Yang QY, 2015, MOLECULES, V20, P12114, DOI 10.3390/molecules200712114